Regression of portal hypertension: underlying mechanisms and therapeutic strategies
Explore this paper's citation graph
Summary
An updated review of the currently available data regarding spontaneous and drug-promoted regression of portal hypertension, paying special attention to the clinical evidence, considers pathophysiological caveats that highlight the need for caution in establishing a new dogma that human chronic liver disease and portal hypertension is reversible.
- Type
- review
- Published
- 2021-02-01
- Cited by
- 34
- References
- 139
- Access
- Open access
- OpenAlex
- https://openalex.org/W3127281112
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:231811652
Keywords
Portal hypertension, Medicine, Hepatology, Cirrhosis, Chronic liver disease
References
- Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.
- Reversibility of hepatic fibrosis in experimentally induced cholestasis in rat.
- Spontaneous regression of oesophageal varices after long-term conservative treatment. Retrospective study in 20 patients with alcoholic liver cirrhosis, posthepatitic cirrhosis and haemochromatosis with cirrhosis.
- Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study
- Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis
- Reversibility of liver fibrosis
- Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis
- The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study
- Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: A randomized controlled trial.
- Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension
- The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
- The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study.
- Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
- Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?
- Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?
- Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis
- Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
- Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy.
- Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection
- Lamivudine for patients with chronic hepatitis B and advanced liver disease.
Cited by
- Pathogenese und Progression der Leberzirrhose: aktuelle Perspektiven
- Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review
- Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
- The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer
- Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis
- Application of Ultrasound Elastography in Assessing Portal Hypertension
- The prognostic relationship between donor age and infectious risk in liver transplant patients with nonalcoholic steatohepatitis: analysis of UNOS database
- Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms
- Analysis of transjugular intrahepatic portosystemic shunt by hemodynamic simulation
- Mechanobiology of portal hypertension
- Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease
- The roles of liver sinusoidal endothelial cells in liver ischemia/reperfusion injury
- From Cirrhosis to the Dysbiosis (A Loop of Cure or Complications?)
- Pathophysiology and therapeutic options for cirrhotic portal hypertension.
- Screening patients in general practice for advanced chronic liver disease using an innovative IT solution: The Liver Toolkit
- Mechanisms and implications of recompensation in cirrhosis
- Hemodynamic comparisons of different shunt positions and geometrical model simplification strategies in the simulation of transjugular intrahepatic portosystemic shunt (TIPS)
- From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension
- A Multi‐Scale Computational Model of the Hepatic Circulation Applied to Predict the Portal Pressure After Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- Preventing the progression of cirrhosis to decompensation and death
Related papers
- P.148 ROLE OF ENDOTHELIN-1 AND CIRCULATING CYTOKINES IN HYPERDYNAMIC CIRCULATION AND PORTOPULMONARY HYPERTENSION IN CIRRHOTIC PATIENTS
- Significant improvement of portopulmonary hypertension after 1-week terlipressin treatment.
- Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients.
- Effect of Terlipressin Administration on Portal Pressure in Patients with Liver Cirrhosis
- Terlipressin and hepatorenal syndrome: what is important for nephrologists and hepatologists.
- The use of vasoconstrictors in patients with liver cirrhosis: how, when, why
- Terlipressin is more effective in decreasing vat&al pressure in cirrhotic patients pressure than portal
- Effects of terlipressin on systolic pulmonary artery pressure of patients with liver cirrhosis: an echocardiographic assessment.
- Are the benefits of beta blockers in cirrhotics only related to decreased portal hypertension
- Terlipressin is more effective in decreasing variceal pressure than portal pressure in cirrhotic patients.